Home Add to Favorite Contact Submit  
           29 March, 2024


    
Category:  Press » Technology

 

Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in Cash

Popularity:
         Views: 1298
2010-10-04 06:41:49     
sanofi-aventis

Sanofi-aventis [(EURONEXT: SAN) and (NYSE: SNY)] announced today it has commenced a tender offer for all outstanding shares of common stock of Genzyme Corporation (Nasdaq: GENZ) for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. The transaction is valued at approximately $18.5 billion. The offer, which was unanimously approved by sanofi-aventis' Board of Directors, is scheduled to expire at 11:59 p.m., New York City time on December 10, 2010.

While sanofi-aventis' strong preference is to engage in constructive discussions with Genzyme, Genzyme's Board and management team's continued refusal to do so has led sanofi-aventis to commence the tender offer. A meeting between the two CEOs on September 20, 2010, proved unproductive, despite several attempts by sanofi-aventis to advance discussions. Sanofi-aventis executives met recently with shareholders who collectively own more than 50 percent of Genzyme's outstanding shares. The conversations revealed that those shareholders were frustrated with Genzyme's persistent refusal to have meaningful discussions regarding sanofi-aventis' proposal. Sanofi-aventis sent a letter to Genzyme's Board today informing it of the company's intention to commence the tender offer, a copy of which is included with this release.

"Sanofi-aventis is committed to a transaction with Genzyme, and we believe that our offer reflects both Genzyme's upside potential and its current operational challenges," said Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis. "Our strong preference has been and continues to be to work together constructively with the Genzyme Board to reach a mutually agreeable transaction, but our attempts to do so have been blocked at every turn. Our recent meetings with Genzyme shareholders demonstrate that they support a transaction and are frustrated by Genzyme's unwillingness to engage in constructive discussions with us. This has left us with no choice but to present the offer directly to Genzyme's shareholders. We strongly believe our offer price of $69 per share in cash represents a compelling value for Genzyme shareholders."

The sanofi-aventis tender offer represents a premium of 38% over Genzyme's unaffected share price of $49.86 on July 1, 2010. Sanofi-aventis' offer also represents a premium of almost 31% over the one-month historical average share price through July 22, 2010, the day prior to press speculation that sanofi-aventis had made an approach to acquire Genzyme.

Today, sanofi-aventis will file with the U.S. Securities and Exchange Commission ("SEC") a Tender Offer Statement on Schedule TO, containing the Offer to Purchase, form of Letter of Transmittal and related tender offer documents, setting forth in detail the terms and conditions of the tender offer. The tender offer is conditioned on, among other things, (i) tender of a majority of the outstanding shares of Genzyme common stock, calculated on a fully-diluted basis, (ii) Genzyme's Board of Directors having approved the tender offer and the subsequent merger described in the tender offer document filed by sanofi-aventis today with the "SEC" such that the restrictions on business combinations with interested shareholders under the General Laws of Massachusetts will be inapplicable to such transactions, (iii) the receipt of required regulatory approvals and (iv) Genzyme not having entered into any transaction or taken other actions that would impair completion of the tender offer or diminish the value of Genzyme to sanofi-aventis. Sanofi-aventis has secured financing for its offer from BNP Paribas, J.P. Morgan Europe Limited and Societe Generale.

Sanofi-aventis' lead financial advisors for this transaction are Evercore Partners and J.P. Morgan and its legal advisor is Weil, Gotshal & Manges LLP.

Conference Call

Sanofi-aventis will hold a call for investors and analysts on Monday, October 4, 2010 at 9.00 a.m. ET / 3.00 p.m. CET to discuss the tender offer. Those wishing to listen and participate should dial one of the following numbers:

France: +33 (0)1 72 00 13 68

UK: +44 203 367 94 53

US: +1 866 907 59 24

Below is the full text of the letter sent today:

October 4, 2010

VIA E-MAIL, TELECOPIER AND DHL

Mr. Henri Termeer
Chairman, President and Chief Executive Officer
Genzyme Corporation
500 Kendall Street
Cambridge, Massachusetts 02142

Dear Henri:

We are disappointed that you remain unwilling to have constructive discussions with us regarding our offer to acquire Genzyme Corporation. We continue to believe that our proposal is compelling for your shareholders and would provide them with immediate and substantial value that reflects the potential of Genzyme's business and pipeline.

Subsequent to making our offer public on August 29, 2010, we met with your largest shareholders owning collectively over 50% of Genzyme's outstanding shares. It was clear from our meetings that your shareholders are supportive of our initiative and, like us, are frustrated with your refusal to have meaningful discussions with us regarding our proposal. Your continued refusal to engage with us in a constructive manner is denying your shareholders an opportunity to receive a substantial premium, to realize immediate liquidity, and to protect against the risks associated with Genzyme's business and operations.

After several months of our repeated requests for a meeting with you, we finally met on September 20, 2010. Unfortunately, this meeting was not productive. In an effort to advance our discussions, I shared a very narrow information request focused on confirming your anticipated manufacturing recovery. Even though we and the market have analyzed and assessed the prospects for alemtuzumab, I proposed a meeting with your commercial team to understand their perspectives on the role alemtuzumab could play in the evolving multiple sclerosis market. You were unwilling to pursue either of these or any other path forward. You were also unwilling to provide us with your perspective on an appropriate valuation for Genzyme.

You have, therefore, left us no alternative but to commence a tender offer and take our offer directly to your shareholders. We strongly believe that our offer price of $69.00 per share in cash is compelling and represents substantial value for Genzyme's shareholders.

This offer represents a premium of 38% over Genzyme's unaffected share price of $49.86 on July 1, 2010, the day prior to the press speculation regarding sanofi-aventis' potential acquisition plans for a large US biotech company. It also represents a premium of almost 31% over the one-month historical average share price through July 22, 2010, the day prior to press speculation that sanofi-aventis had made an approach to acquire Genzyme.

We believe that a combination of our two businesses would be beneficial to our respective shareholders and employees, and the patients and physicians we serve. Sanofi-aventis would put its full resources behind Genzyme to invest in developing new treatments, enhance penetration in existing markets and further expand into emerging markets. Sanofi-aventis is well positioned to help Genzyme address its manufacturing problems. Genzyme would become the global center for excellence for sanofi-aventis in rare diseases and this unit would be managed as a stand-alone division under the Genzyme brand, with its own R&D, manufacturing and commercial infrastructure. Genzyme's management and employees would play a key role within sanofi-aventis, and the combination would further increase sanofi-aventis' presence in the greater Boston area.

It remains our strong preference to work together with you to reach a mutually agreeable transaction. However, given your unwillingness to engage in constructive discussions with us, we had no choice but to commence a tender offer. Given our commitment to this transaction, we will continue to consider all alternatives for consummating an acquisition of Genzyme. We believe it is in the best interests of both companies, and our respective shareholders and other constituencies, to move forward quickly to complete this transaction. We and our advisors are available to meet with you to discuss the terms of our offer and to conclude a transaction expeditiously.

Yours sincerely,
By: /s/ Christopher A. Viehbacher
Christopher A. Viehbacher
Chief Executive Officer

Cc: Genzyme Board of Directors

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Additional Information

This communication is neither an offer to purchase nor a solicitation of an offer to sell any securities. In connection with the proposed transaction, sanofi-aventis and GC Merger Corp. will file tender offer documents with the U.S. Securities and Exchange Commission (the "SEC"). These documents will be mailed to all Genzyme shareholders of record. These documents, as they may be amended from time to time, contain important information about the proposed transaction and Genzyme shareholders are urged to read them carefully and in their entirety before any decision is made with respect to the proposed transaction. The tender offer materials may be obtained at no charge by directing a request by mail to MacKenzie Partners, Inc., 105 Madison Avenue, New York, New York 10016, or by calling toll-free at 1-800-322-2885, and may also be obtained at no charge at the website maintained by the SEC at www.sec.gov.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends" "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2009. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Specialized in: Sanofi-aventis - Outstanding Shares - Genzyme - Cash
URL: http://en.sanofi-aventis.com/
Print press release      Bookmark this page
Related Press releases 
Revolutionizing Image Quality with MTF Testing in Oxfordshire (Popularity: ): In the heart of Oxfordshire, a technological revolution in image quality is unfolding, driven by the principles of Modulation Transfer Function (MTF) Testing and Measurement. This advancement is not just a technical leap; it's a commitment to visual perfection in numerous fields, from high-end photography to scientific research.MTF Testing is a sophisticated method used to evaluate the performance of optical systems, such as cameras, lenses, and scanners. By measuring the ...
Clipto Introduces Cutting-Edge AI Transcription Service (Popularity: ): Clipto, a leading innovator in the field of artificial intelligence, proudly announces the launch of its state-of-the-art AI Transcription Service, revolutionizing the way businesses manage and document their audio content.In an era where efficiency and precision are paramount, Clipto's AI Transcription Service harnesses the power of advanced artificial intelligence algorithms to convert spoken words into accurate and highly readable text. This service caters to a diverse range of industries, from ...
Future Electronics Features ECS Inc. ECX-2236 SMD Crystal in THE EDGE (Popularity: ): Montreal, Canada (press.abc-directory ) October 24, 2022 - Future Electronics, a global leading distributor of electronic components, is offering the low profile, versatile ECX-2236 by ECS Inc. in the latest edition of THE EDGE.Operating in a -20°C to +70°C temperature range, the ECX-2236 family includes extended range options that operate from -40°C to +125°C. They provide a 5pF maximum shunt capacitance and an 8pF typical load capacitance. The ECX-2236 SMD ...
Munich service robot can provide support during the COVID 19 pandemic (Popularity: ): Munich, Bavaria ( press.abc-directory.com ) April 8, 2020 - The technology company Robotise wants to help quickly alleviate current staff shortages in hospitals, doctors' practices and nursing homes.The company is modifying its JEEVES service robot for this purpose. The 1.10-meter-high robot has been used primarily for minibar and room service in hotels until now. But the robotic butler will now be used as an autonomous assistant for the health sector. ...
Panasonic PAN1326C2 Series Bluetooth® RF Module Featured in The Edge by Future Electronics (Popularity: ): Montreal, Canada (press-abc-directory) March 9, 2020 - Future Electronics, a global leading distributor of electronic components, is featuring a Bluetooth® implementation module by Panasonic in this month's edition of THE EDGE.This Panasonic PAN1326C2 Bluetooth 4.2-compliant Host Controlled Interface (HCI) brings Texas Instrument's seventh-generation Bluetooth® core integrated circuit to an easy-to-use format. The PAN1326C2 offers best-in-class RF performance, increased range and a tiny footprint with as little as two layers, making ...


Related Business 
Discount Medical Supplies (Popularity: ): Main Street Vaccines is a national physician purchasing group with over 7,000 members. We offer the lowest contract prices on a full line of Sanofi Pasteur and Merck vaccines, plus cash rebates and bonuses. This service gives you the convenience of one stop shopping for Sanofi Pasteur vaccines and all the professional supplies you use in your office.
Tender Alert (Popularity: ): Team TenderAlert.in is dedicated to achieve the top notch in the e-Procurement services, we are collecting the information about the tenders, bids and project from various sources like New Papers, Web Sites and Department / Organization. Every tender comes with new opportunity and we are providing the alert and information to you, We are not only providing the tender information we also share Tender Corrigendum, Tender Document, Minutes of Pre ...
Tender Reader (Popularity: ): Tender Reader is One of The Biggest Tender Portal in India, We Have Large Database of Government Tender and Private Tender, Catch Latest Tender And Tenders Information, Tender Notice, e Tender Online in India.
Sanofi-Synthelabo Inc. (Popularity: ): The U.S. subsidiary of Sanofi-Synthelabo, a global healthcare company, with annual sales in excess of $6 billion and 30,000 employees in more than 100 countries.
Acomplia Generic Rimonabant (Popularity: ): Acomplia Generic Rimonabant / Zimulti are the new weight loss medication breakthrough from Sanofi-Aventis, exceeding Phentermine in its ability to help you lose the weight. Buy Acomplia Generic Rimonabant online at Pharmaciesstore.
Cash Loan Solution (Popularity: ): Provides online cash advance, faxless payday loans and quick and easy payday cash with no fax no credit checks. We are one of the best and one of the most trusted online payday loan and cash advance companies in the business. With easily understandable eligibility criteria and a simple application procedure, we assist all our customers to acquire their cash fast, easily and without any hassles.
Cash Advance Loans (Popularity: ): Provides payday loans quick and easy cash advances nationwide. Cash advances and short term loans with no credit checks required. We are one of the best and one of the most trusted online payday loan and cash advance companies in the business. With easily understandable eligibility criteria and a simple application procedure, we assist all our customers to acquire their cash fast, easily and without any hassles.
Aventis Oncology (Popularity: ): Treatments and programs, including Taxotere (docetaxel), Anzemet (dolasetron mesylate), PACT+SM, and www.1800RxTrial.com, plus breaking news on Aventis agents in development.
Quick Cash Advance (Popularity: ): Our cash advance services are tailor made for people who are looking for fast cash. Apply for cash advance UK, quick cash, payday cash, emergency cash, no faxing cash advance and online cash. Avail cash loans and wave off your cash crisis.
Australian Tenders (Popularity: ): Information for Principals: Submitting a tender is a great way to earn new business. Here you get Australian Tenders, Tender Services, Austenders etc. at one place. Australian Tenders, Online Australian Tenders, Australian Tender, Australian Government Tenders, Australian Government Tender, Government Tenders Services, Tender Services, Australian Tender Services.